Roka Goes Public in $60M Stock Offering | GenomeWeb

NEW YORK (GenomeWeb) – Roka Bioscience today priced its initial public offering of 5 million shares at $12 per share, raising gross proceeds of $60 million.

The Warren, NJ-based firm, which makes molecular diagnostic tests for foodborne pathogens, will begin trading today on the Nasdaq Global Market under the ticker symbol "ROKA". The share price is below the previously anticipated range of $14 to $16 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.